95 results
Page 3 of 5
8-K
EX-99.1
9b485f
18 Mar 22
InMed Announces Management Changes
1:02pm
8-K
EX-99.1
k03ugia1cmw
9 Mar 22
InMed to Present at the 34th Annual Roth Conference
12:58pm
8-K
EX-99.1
r6v8yd
15 Feb 22
Regulation FD Disclosure
1:17pm
S-3
1qygh4y9q8
4 Feb 22
Shelf registration
4:36pm
8-K
EX-99.1
ccobgi5f2cfb33lo
19 Jan 22
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
4:09pm
8-K
EX-99.1
p6e6s
5 Jan 22
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
2:22pm
8-K
EX-99.1
nofqs 0185mq3bh1giji
10 Nov 21
InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update
1:08pm
8-K
EX-99.1
373sc6jtu30
3 Nov 21
Other Events
2:00pm
DEF 14A
tduhd5b
28 Oct 21
Definitive proxy
3:07pm
8-K
EX-2.1
at7zq6v ww
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
8-K
EX-99.1
h13e px344p
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
8-K
EX-99.1
m29e 6wghrojdfr80
30 Sep 21
Regulation FD Disclosure
1:30pm
8-K
EX-99.1
biqyocc1xex em6d4t
24 Sep 21
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update
4:07pm
10-K
5s8ev7
24 Sep 21
Annual report
7:31am
10-K
EX-2.1
7ixrh9
24 Sep 21
Annual report
7:31am
8-K
EX-99.1
8u8lo5bbuaiq92
20 Sep 21
Regulation FD Disclosure
1:09pm
8-K
EX-99.1
ifhb08x
13 Sep 21
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
8:00am
424B3
bvq5r
22 Jul 21
Prospectus supplement
10:27am